HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Analgesic effects of cannabinoid receptor agonist WIN55,212-2 in the nucleus cuneiformis in animal models of acute and inflammatory pain in rats.

Abstract
Nucleus cuneiformis (NCF) along with periaqueductal gray (PAG) and rostral ventromedial medulla (RVM) is a part of descending system for pain modulation. Cannabinoids have analgesic effects on the PAG and RVM. This study investigates the possible role of cannabinoids in pain modulation in the NCF. Cannabinoid agonist, WIN55,212-2 (5, 10 and 20μg/0.3μl DMSO per side), and selective cannabinoid CB1 receptor antagonist, AM251(1, 5 and 10μg/0.3μl DMSO per side), were microinjected alone or in succession. As models of acute and inflammatory pain, tail-flick and formalin test were utilized to examine the effects of these drugs on pain modulation in 5min time blocks for 60min. Results of tail-flick and formalin tests demonstrated a dose-dependent analgesic effects for WIN55,212-2, with the most significant response at the dose of 20μg/side. The analgesic responses were more effective during the first 45-min period of the tail-flick test (P<0.001) and during the late phase (P<0.001) of formalin test, compared to the early phase (P<0.05). These analgesic effects were blocked in the presence of AM251 (1μg/0.3μl DMSO per side) in both tests. Administration of AM251 alone did not have any effect on nociceptive responses in either test. The cannabinoid-mediated analgesia demonstrated in this study suggests the presence of a cannabinoid-sensitive nociceptive modulatory system in the NCF.
AuthorsMohammad Ebrahimzadeh, Abbas Haghparast
JournalBrain research (Brain Res) Vol. 1420 Pg. 19-28 (Oct 28 2011) ISSN: 1872-6240 [Electronic] Netherlands
PMID21911208 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2011 Elsevier B.V. All rights reserved.
Chemical References
  • Analgesics
  • Benzoxazines
  • Cannabinoid Receptor Agonists
  • Cannabinoid Receptor Antagonists
  • Morpholines
  • Naphthalenes
  • Piperidines
  • Pyrazoles
  • Receptors, Cannabinoid
  • Formaldehyde
  • AM 251
  • (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone
Topics
  • Analgesics (therapeutic use)
  • Analysis of Variance
  • Animals
  • Area Under Curve
  • Benzoxazines (therapeutic use)
  • Cannabinoid Receptor Agonists
  • Cannabinoid Receptor Antagonists
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Formaldehyde (adverse effects)
  • Hot Temperature (adverse effects)
  • Inflammation (complications)
  • Male
  • Medulla Oblongata (drug effects, physiology)
  • Microinjections (methods)
  • Morpholines (therapeutic use)
  • Motor Activity (drug effects)
  • Naphthalenes (therapeutic use)
  • Pain (drug therapy)
  • Pain Measurement
  • Piperidines (pharmacology)
  • Pyrazoles (pharmacology)
  • Rats
  • Rats, Wistar
  • Receptors, Cannabinoid (metabolism)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: